ZA201407544B - Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt - Google Patents

Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt

Info

Publication number
ZA201407544B
ZA201407544B ZA2014/07544A ZA201407544A ZA201407544B ZA 201407544 B ZA201407544 B ZA 201407544B ZA 2014/07544 A ZA2014/07544 A ZA 2014/07544A ZA 201407544 A ZA201407544 A ZA 201407544A ZA 201407544 B ZA201407544 B ZA 201407544B
Authority
ZA
South Africa
Prior art keywords
rosuvastatin
salt
pharmaceutical composition
olmesartan medoxomil
medoxomil
Prior art date
Application number
ZA2014/07544A
Other languages
English (en)
Inventor
Jun-Ku Kim
Bok-Ki Kang
Hee-Chul Chang
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49260650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201407544(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of ZA201407544B publication Critical patent/ZA201407544B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2014/07544A 2012-03-30 2014-10-17 Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt ZA201407544B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120032903 2012-03-30
PCT/KR2013/002378 WO2013147462A1 (en) 2012-03-30 2013-03-22 Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt

Publications (1)

Publication Number Publication Date
ZA201407544B true ZA201407544B (en) 2015-12-23

Family

ID=49260650

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/07544A ZA201407544B (en) 2012-03-30 2014-10-17 Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt

Country Status (22)

Country Link
US (1) US20150050333A1 (forum.php)
EP (1) EP2830618B1 (forum.php)
JP (1) JP6122098B2 (forum.php)
KR (2) KR101451081B1 (forum.php)
CN (1) CN104220068B (forum.php)
AU (1) AU2013240846B2 (forum.php)
CA (1) CA2866377C (forum.php)
CL (1) CL2014002581A1 (forum.php)
CY (1) CY1117909T1 (forum.php)
DK (1) DK2830618T3 (forum.php)
ES (1) ES2587912T3 (forum.php)
HU (1) HUE030674T2 (forum.php)
IN (1) IN2014MN01919A (forum.php)
LT (1) LT2830618T (forum.php)
MX (1) MX362400B (forum.php)
MY (1) MY166288A (forum.php)
PH (2) PH12014501813B1 (forum.php)
PT (1) PT2830618T (forum.php)
RU (1) RU2616516C2 (forum.php)
SG (2) SG10201502582PA (forum.php)
WO (1) WO2013147462A1 (forum.php)
ZA (1) ZA201407544B (forum.php)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0752842Y2 (ja) 1989-10-04 1995-12-06 タカヤマ金属工業株式会社 樋支持具
KR20170083071A (ko) * 2014-11-11 2017-07-17 시오노기 앤드 컴파니, 리미티드 광에 대해서 불안정한 약물을 함유하는 다층 정제
CN107205987A (zh) * 2015-01-09 2017-09-26 奥托泰利克有限责任公司 根据auc进行奥美沙坦给药的方法
CN106727579A (zh) * 2015-11-19 2017-05-31 哈尔滨圣吉药业股份有限公司 一种厄贝沙坦/瑞舒伐他汀复方制剂及其制备方法
CN106727580A (zh) * 2015-11-19 2017-05-31 哈尔滨圣吉药业股份有限公司 一种阿利沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105395551A (zh) * 2015-11-19 2016-03-16 哈尔滨圣吉药业股份有限公司 一种奥美沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105232556A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种坎地沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
US9989543B2 (en) 2016-01-11 2018-06-05 Autotelic, Llc Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
WO2018009842A1 (en) * 2016-07-08 2018-01-11 Autotelic Llc Methods for rosuvastatin dosing by auc
MY198062A (en) * 2017-07-17 2023-07-31 Lilly Co Eli Pharmaceutical compositions
KR101992400B1 (ko) * 2018-04-30 2019-06-24 보령제약 주식회사 약학적 제제
BR112021016766A2 (pt) * 2019-02-26 2021-10-13 Daewoong Pharmaceutical Co., Ltd. Composição farmacêutica de uma única forma de posologia
KR20220026641A (ko) * 2020-08-25 2022-03-07 주식회사 대웅제약 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
CN113398086A (zh) * 2021-05-18 2021-09-17 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊
CN113476423A (zh) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
JP2002145770A (ja) * 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
CA2656181C (en) * 2006-06-27 2011-09-06 Daiichi Sankyo Company, Limited Compressed preparation of compositions comprising olmesartan medoxomil
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
MX2009004681A (es) * 2006-10-30 2009-08-19 Hanall Pharmaceutical Co Ltd Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa.
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
TWI482641B (zh) * 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
TWI488658B (zh) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd 溶出性之改善方法
TW200927197A (en) * 2007-10-29 2009-07-01 Daiichi Sankyo Co Ltd Film coated preparation
US20110009482A1 (en) * 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
JP5554699B2 (ja) * 2008-03-13 2014-07-23 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
US10574932B2 (en) * 2008-07-28 2020-02-25 Fox Digital Enterprises, Inc. System and method of generating subtitling for media
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
US8399011B1 (en) * 2012-08-10 2013-03-19 Magnifica Inc. Oral particle compositions containing a core and an acid-soluble coat

Also Published As

Publication number Publication date
SG10201502582PA (en) 2015-05-28
RU2014143536A (ru) 2016-05-27
MX2014011510A (es) 2014-12-05
KR101451081B1 (ko) 2014-10-16
EP2830618A4 (en) 2015-08-05
AU2013240846A1 (en) 2014-08-28
CN104220068A (zh) 2014-12-17
MY166288A (en) 2018-06-25
JP6122098B2 (ja) 2017-04-26
RU2616516C2 (ru) 2017-04-17
JP2015511635A (ja) 2015-04-20
KR20140085411A (ko) 2014-07-07
CL2014002581A1 (es) 2015-01-09
ES2587912T3 (es) 2016-10-27
PH12014501813A1 (en) 2014-11-24
HK1200107A1 (en) 2015-07-31
EP2830618B1 (en) 2016-07-27
KR101931195B1 (ko) 2018-12-21
US20150050333A1 (en) 2015-02-19
IN2014MN01919A (forum.php) 2015-07-10
EP2830618A1 (en) 2015-02-04
HUE030674T2 (en) 2017-06-28
SG11201405198YA (en) 2014-09-26
LT2830618T (lt) 2016-09-26
AU2013240846B2 (en) 2017-02-02
PT2830618T (pt) 2016-11-04
PH12014501813B1 (en) 2014-11-24
CA2866377C (en) 2020-02-11
PH12016500420A1 (en) 2017-04-10
CY1117909T1 (el) 2017-05-17
CN104220068B (zh) 2017-08-04
WO2013147462A1 (en) 2013-10-03
MX362400B (es) 2019-01-16
DK2830618T3 (en) 2016-10-03
CA2866377A1 (en) 2013-10-03
KR20130111335A (ko) 2013-10-10

Similar Documents

Publication Publication Date Title
ZA201407544B (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
IL274988A (en) Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
ZA201500451B (en) Dihydropyrimidine compounds and their application in pharmaceuticals
PT2920149T (pt) Compostos de 3-aminocicloalquil como inibidores de ror-gama-t e utilizações dos mesmos
ZA201500899B (en) Titanium diboride composition in pcbn
AP3611A (en) Heterocyclic compounds and their uses
ZA201409508B (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
IL237146A0 (en) Pharmaceutical compound containing Rabamipide
PH12014500542A1 (en) Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
IL231096A (en) Theses are converted into 2- (novel-6-Iloxy) and used as pharmaceutical preparations
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors
ZA201305014B (en) Method for the formation and analysis of sulfited-tetrameric,-trimeric,-dimeric and -monomeric compounds from commercial proanthocyanidins, and the use of said sulfited compounds in pharmaceutical applications